Skip to main content

Table 5 Univariate and multivariate analysis of prognostic factors of overall, cancer-specific and disease-free survival by Cox regression model

From: Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model

Variables

Overall survival

Cancer-specific survival

 

Disease-free survival

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

HR

p

HR (95% CI)

p

HR

p

HR (95% CI)

p

HR

p

HR (95% CI)

p

Sex (male)

0.92

0.525

  

0.93

0.634

  

0.87

0.290

  

Age (≥65 years)

1.7

0.000

1.41 (1.10-1.80)

0.007

1.73

0.000

1.51 (1.16-1.96)

0.002

1.48

0.001

1.19 (0.94-1.50)

0.146

Alcohol (yes)

0.89

0.445

  

0.88

0.446

  

0.93

0.609

  

Tobacco (yes)

1.24

0.160

  

1.27

0.133

  

1.15

0.336

  

Family history (yes)

1.22

0.564

 

0.81

0.561

0.561

  

2.09

0.007

2.13 (1.23-3.69)

0.007

Histological type

            

   Papillary

1

 

1

 

1

   

1

   

   Non-papillary

1.83

0.061

  

1.77

0.093

  

1.89

0.038

1.42 (0.77-2.62)

0.260

   Tubular

1.54

0.213

  

1.51

0.263

  

1.58

0.166

  

   Poorly differentiated

1.93

0.045

1.66 (0.86-3.19)

0.129

1.88

0.069

  

2.06

0.020

1.62 (0.88-3.01)

0.124

   Mucinous

1.72

0.127

  

1.68

0.166

  

1.66

0.135

  

   Signetring cell

2.39

0.022

1.78 (0.83-3.79)

0.137

2.09

0.066

  

2.33

0.021

1.91 (0.93-3.91)

0.078

Tumor grade (G3-G4)

1.25

0.066

  

1.19

0.175

  

1.26

0.049

1.19 (0.93-1.50)

0.162

Tumor stage (III-IV)

4.87

0.000

2.18 (1.48-3.22)

0.000

5.45

0.000

2.46 (1.62-3.72)

0.000

3.58

0.000

2.04 (1.46-2.84)

0.000

Depth of invasion (T3-T4)

4.58

0.000

1.22 (0.67-2.22)

0.511

4.78

0.000

1.18 (0.63-2.21)

0.597

2.48

0.000

0.81 (0.50-1.32)

0.405

Lymph node (N1-N3)

5.6

0.000

2.34 (1.35-4.05)

0.003

5.36

0.000

2.12 (1.21-3.74)

0.009

3.05

0.000

1.39 (0.91-2.14)

0.132

Distant metastasis (M1)

4.61

0.000

2.14 (1.56-2.93)

0.000

5.07

0.000

2.09 (1.50-2.92)

0.000

3.73

0.000

2.06 (1.52-2.81)

0.000

CEA (>5 ng/ml)

1.66

0.000

0.87 (0.67-1.14)

0.323

1.74

0.000

0.93 (0.70-1.24)

0.610

1.53

0.000

0.85 (0.66-1.11)

0.237

CA199 (>37 U/ml)

1.95

0.000

1.16 (0.89-1.51)

0.275

2.14

0.000

1.30 (0.98-1.72)

0.065

1.92

0.000

1.33 (1.03-1.72)

0.028

NLR (≥2.36)

2.34

0.000

1.13 (0.68-1.87)

0.648

2.56

0.000

1.53 (1.11-2.11)

0.010

2.10

0.000

1.38 (1.04-1.82)

0.025

dNLR (≥1.85)

2.12

0.000

1.42 (1.08-1.87)

0.012

2.23

0.000

1.10 (0.66-1.85)

0.713

1.92

0.000

1.08 (0.69-1.69)

0.722

PLR (≥132)

1.51

0.001

1.03 (0.78-1.35)

0.858

1.56

0.001

0.96 (0.71-1.28)

0.763

1.42

0.003

0.94 (0.72-1.23)

0.674

LMR (≥4.95)

0.49

0.000

1.00 (0.73-1.35)

0.977

0.44

0.000

1.00 (0.71-1.40)

0.995

0.55

0.000

0.98 (0.73-1.32)

0.907

  1. HR, hazard ratio; CI, confidence interval; NLR, neutrophil count to lymphocyte count; dNLR, neutrophil count to (white cell count – neutrophil count); PLR, platelet count to lymphocyte count; LMR, lymphocyte to monocyte ratio.
  2. aGrade 1 and 2 stand for high or middle differentiated tumor, grade 3 and 4 stand for poorly differentiated tumor.
  3. bTumor stage according to seventh edition of American Joint of Committee on Cancer.